The National Institute for Health and Care Excellence (NICE) has today published final draft guidance recommending a new treatment for people with diabetic macular oedema (DMO). DMO is the most common ...

Joseph M. Coney, MD, FACS, reviews best practices for improving adherence to treatment among patients with diabetic macular edema through comprehensive education on the disease and available therapies ...

March 26, 2007 – New York, NY -- The Juvenile Diabetes Research Foundation, the world’s largest charitable funder of type 1 diabetes research, announced that the Ranibizumab for Edema of the mAcula in ...

For people living with diabetes, vision complications require immediate attention. Diabetic macular edema (DME), a condition causing fluid buildup in the eye’s central retina, demands particular ...

Exonate Ltd. (the Company), an mRNA therapy company focused on treatments for diabetic complications, today announced its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a ...

CAMBRIDGE, England & NOTTINGHAM, England--(BUSINESS WIRE)--Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases ...

Point-of-care AI-DR can instantly diagnose diabetic retinopathy and diabetic eye oedema in five to 10 seconds. It can locate from fundus images four main lesions – microaneurysms, haemorrhages, soft ...

Placebo-controlled trial findings show that lipoprotein-associated phospholipase A 2 (Lp-PLA 2) inhibition modestly benefits the vision of patients with centre-involved diabetic macular oedema (DME) ...

Boehringer Ingelheim has initiated the THULITE Phase II trial to evaluate the safety, tolerability and efficacy of BI 1815368, an oral treatment aimed at improving vision for individuals with diabetic ...

The National Institute for Health and Care Excellence (NICE) has recommended a new treatment option for people with diabetic macular oedema (DMO) with thousands of people set to benefit from the ...